cgi-1842
Small moleculeexperimental
Clinical trial activity
2 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Feb 1, 2009 (NCT00842335)
Timeline
2000s
- Jan 1, 2009
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
PDGFRB inhibitor
KDR inhibitor
- Ephrin type-B receptor 4INHIBITOR
EPHB4 inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
COc1ccc(Br)cc1NC(=O)Nc1cccc2c1ccn2Cc1ccnc(N)c1- Mol. weight
- 466.34 g/mol
- Lipinski Ro5
- 1 violation(s)
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL3545155 ↗
Also known as
- 1-(1-(2-amino-pyridin-4-ylmethyl)-1h-indol-4-yl)-3-(5-bromo-2-methoxyphenyl)urea
- cgi-1842
- cgi-1842
- cgi-1842
- ji 101
- ji-101
- ji-101
- ji-101
- ji-101
- ji101 cpd
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT01149434 | Phase 1/Phase 2 (Phase 2) | Sep 1, 2010 | Jubilant Innovation Ltd., University of Utah |
| NCT00842335 | Phase 1/Phase 2 (Phase 2) | Feb 1, 2009 | Jubilant Innovation Ltd. |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Jubilant Innovation Ltd. | For profit | 2 | 1 | 1 | 2009 |
| University of Utah | Academic/Hospital | 1 | 1 | 1 | 2010 |
2 organizations
Page 1 / 1